AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1514168
Drug: GR32191 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR32191 (40 mg) + heparin (5,000 IU bolus + 1,000 IU/h for 3 h)
Trial: 1514168
Drug: GR32191 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR32191 (40 mg) + placebo
Trial: 1514168
Drug: GR32191 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR32191 (80 mg) + placebo
Trial: 1514168
Drug: heparin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin + placebo
Trial: 6098035
Drug: Penicillin-sulbactam regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin-sulbactam regimen (aqueous procaine penicillin G, sulbactam, and probenecid)
Trial: 18379485
Drug: Bitemporal transcranial
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitemporal transcranial magnetic therapy
Trial: 16251627
Drug: Serum ferritin
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum ferritin concentrations > 160 microg/L in women
Trial: 8891015
Drug: UVB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB therapy
Trial: 12040250
Drug: Angiotensin‐converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐converting enzyme inhibitor (ACE‐I)
Trial: 17190733
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor antagonist (ARB)
Trial: 31164368
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (conventional or sensor-augmented pump therapy)
Trial: 10770448
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg/day)
Trial: 15067257
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment need assessed by the aesthetic component (AC) of the index of orthodontic treatment need (IOTN)
Trial: 15067257
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment need assessed by the dental health component (DHC) of the index of orthodontic treatment need (IOTN)
Trial: 15067257
Drug: Subjective need
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjective need for orthodontic treatment as assessed by a prestructured questionnaire
Trial: 9713781
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.4 mg/mL for 2 minutes
Trial: 9713781
Drug: Control balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control balanced salt solution
Trial: 7993985
Drug: Single 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 750 mg oral dose of Vigabatrin (VGB)
Trial: 3281387
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine
Trial: 29358543
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message reminders about oral hygiene
Trial: 19663522
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg/day)
Trial: 22103958
Drug: Combination pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination pharmacotherapy (nicotine patch + nicotine lozenge, bupropion + nicotine lozenge)
Trial: 22103958
Drug: Monotherapy (nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (nicotine patch, nicotine lozenge, bupropion)
Trial: 11403509
Drug: Combination treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatments
Trial: 12967792
Drug: Verteporfin therapy
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin therapy (Visudyne, Novartis AG)
Trial: 1734249
Drug: Prophylactic nonabsorbable
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic nonabsorbable antibiotics (tobramycin, colistin sulfate, and amphotericin B) administered through a nasogastric tube
Trial: 1734249
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered through a nasogastric tube
Trial: 1734249
Drug: Prophylactic nonabsorbable
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic nonabsorbable antibiotics
Trial: 30938654
Drug: 4 mini-implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mini-implants
Trial: 30938654
Drug: 2 mini-implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mini-implants
Trial: 30938654
Drug: 2 standard
RxNorm normalized name: Onguard2 Standard 20 mm Vial Adaptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 standard implants
Trial: 9383925
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (15 minutes a day for 30 days)
Trial: 9383925
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (control group)
Trial: 320940
Drug: 1% clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clotrimazole solution
Trial: 30078167
Drug: remifentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil + methadone (MET) (0.1 mg/kg IV over 15 min)
Trial: 30078167
Drug: remifentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil + magnesium (MAG) (50 mg/kg bolus over 30 min followed by 10 mg/kg/h)
Trial: 26643501
Drug: CRUSADE score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRUSADE score >40 with 24-month dual antiplatelet therapy
Trial: 26643501
Drug: CRUSADE score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRUSADE score ≤40 with 24-month dual antiplatelet therapy
Trial: 26643501
Drug: CRUSADE score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRUSADE score >40 with 6-month dual antiplatelet therapy
Trial: 18831886
Drug: Risedronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5 mg/day) and calcium (900 mg/day)
Trial: 18831886
Drug: Calcium (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (900 mg/day) alone
Trial: 11268446
Drug: Oral HCFU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HCFU, 300 mg daily for 52 weeks starting 2 weeks after surgery
Trial: 8256242
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (1 mg)
Trial: 8256242
Drug: Budesonide (1
RxNorm normalized name: budesonide (11.beta.,16.alpha.(S))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (1 mg)
Trial: 27219886
Drug: Synbiotic supplements
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplements containing 3 probiotic bacteria (Lactobacillus acidophilus 2×10^9, Lactobacillus casei 2×10^9, Bifidobacterium bifidum 2×10^9 CFU/g) plus 800 mg inulin
Trial: 26133741
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n=45)
Trial: 23247052
Drug: Pharmacological weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological weight loss treatment
Trial: 18957616
Drug: Insulin with
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin with BQ-123 (type A endothelin receptor antagonist)
Trial: 18957616
Drug: Insulin with
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin with BQ-123
Trial: 18957616
Drug: Insulin (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (higher dosing in obese subjects)
Trial: 1616160
Drug: Physician-controlled administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician-controlled administration of alfentanil
Trial: 1616160
Drug: Patient-controlled administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled administration of alfentanil
Trial: 15374134
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg paroxetine daily for 42 days
Trial: 6799848
Drug: Other drugs
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drugs (not specified)
Trial: 2822878
Drug: Minimum effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum effective dosage of ACE inhibitors
Trial: 2822878
Drug: Supine rest,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine rest, infusion of angiotensin II, atropine, saline
Trial: 27314763
Drug: Brief parent‐delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief parent‐delivered treatment for child anxiety
Trial: 27314763
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with strategies specifically targeting parental tolerance of their child's negative emotions
Trial: 25714521
Drug: Clipping or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clipping or coiling treatment (specifics on dosage and duration not available)
Trial: 23225796
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of clopidogrel (aspirin 100 mg + clopidogrel 150 mg daily)
Trial: 23225796
Drug: Cilostazol (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (aspirin 100 mg + clopidogrel 75 mg + cilostazol 100 mg bid daily)
Trial: 19906658
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200 mg bimonthly)
Trial: 11970744
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 40 mg four times daily (n=403)
Trial: 1521670
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg buflomedil given orally twice daily for 90 days
Trial: 29972120
Drug: Suspension exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension exercise training in addition to routine rehabilitation training
Trial: 26182441
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 4 mg/kg
Trial: 20692030
Drug: Pentavalent rotavirus
RxNorm normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent rotavirus vaccine (2 mL, three oral doses at 6, 10, and 14 weeks of age)
Trial: 20692031
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three oral doses)
Trial: 25080553
Drug: Pentavalent rotavirus
RxNorm normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent rotavirus vaccine
Trial: 9469358
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 20 mg/m2
Trial: 9469358
Drug: Bleomycin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin and vincristine (BV) combination
Trial: 7637156
Drug: Amrinone infusion
RxNorm normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amrinone infusion
Trial: 480949
Drug: Diethylstilbestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES) 5 mg orally t.i.d.
Trial: 480949
Drug: Diethylstilbestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES) 5 mg orally t.i.d. + Chlorambucil (CB) 0.1‐‐0.2 mg/kg/day orally
Trial: 17288611
Drug: Tetracaine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 4% gel applied to the skin for 30 minutes
Trial: 17288611
Drug: Sucrose administration
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose administration (24% sucrose)
Trial: 27084728
Drug: Tiotropium Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat 5 μg once daily
Trial: 27084728
Drug: Tiotropium HandiHaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium HandiHaler 18 μg once daily
Trial: 12685617
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nitrate treatment)
Trial: 10099056
Drug: Tiazac (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiazac (240 mg single dose)
Trial: 10099056
Drug: Cardizem CD
RxNorm normalized name: Cardizem CD
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardizem CD (240 mg single dose)
Trial: 2679397
Drug: Allopurinol mouth
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol mouth wash (4-5 times daily before and after treatment)
Trial: 31476260
Drug: Percutaneous valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous valve repair plus medical treatment (n=152)
Trial: 31476260
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment alone (n=152)
Trial: 18365222
Drug: Postoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative administration of 0.1 mg fentanyl + 5 ml bupivacaine 0.5%
Trial: 18365222
Drug: Postoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative administration of 5 ml bupivacaine 0.5% alone
Trial: 17803345
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 40 mg/day
Trial: 15465069
Drug: Psychotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy or antidepressant medications
Trial: 11396760
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of tissue adhesive N-butyl-2-cyanoacrylate (group 2, 18 patients)
Trial: 9849455
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus filgrastim
Trial: 598635
Drug: Isosorbide dinitrate,
RxNorm normalized name: isosorbide dinitrate, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate, 5 mg sublingually
Trial: 598635
Drug: Propranolol, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 40 mg orally
Trial: 31402145
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A deficiency (retinol <0.7 μmol/L)
Trial: 28870407
Drug: D2/3 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2/3 receptor availability in striatal regions (including bilateral ventral pallidum/nucleus accumbens, right ventral caudate, and putamen)
Trial: 28870407
Drug: D2/3 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2/3 receptor availability in the caudal portion of the ventral striatum (NAc/vPAL)
Trial: 26251413
Drug: Group cognitive-behavioural
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioural therapy (RAFT) delivered by local rheumatology clinical teams, consisting of 6 sessions of 2 hours each (weeks 1-6) and a 1-hour consolidation session (week 14).
Trial: 26251413
Drug: Group cognitive-behavioural
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioural therapy (RAFT).
Trial: 16849756
Drug: Window therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Window therapy (various agents including ifosfamide, etoposide, doxorubicin, topoisomerase I poisons)
Trial: 16849756
Drug: Ifosfamide/topoisomerase II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide/topoisomerase II inhibitor trials
Trial: 16154241
Drug: Aerosol measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol measles vaccine (10(3.58) CCID50/0.1 mL)
Trial: 17038828
Drug: Aerosol measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol measles vaccine
Trial: 21742842
Drug: Subcutaneous measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous measles vaccine
Trial: 31466854
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg with carboplatin and etoposide
Trial: 25886645
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) containing anti-JEV neutralizing antibody (ImmunoRel, 400mg/kg/day for 5 days)
Trial: 16324780
Drug: 20,000 UI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20,000 UI of lyophilized HAase (5 ml)
Trial: 14998735
Drug: Cue-dose training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cue-dose training (n = 16)
Trial: 3553874
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine in elderly subjects (70% vaccinated)
Trial: 3553874
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine in younger subjects (50% vaccinated)
Trial: 3553874
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine in younger subjects
Trial: 21773992
Drug: PTH(1-84) 100
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH(1-84) 100 µg daily for 24 weeks
Trial: 19435203
Drug: Mixed sorbent
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed sorbent (microcellulose + polysorb) (6g), administered once a week, on average 20 days after operation.
Trial: 8270988
Drug: Arm D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm D: E 130 mg/m2 by 24-hour infusion and P 45 mg/m2 by 24-hour infusion on day 2 and 3 only
Trial: 2572797
Drug: L-tyrosine (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tyrosine (9 g daily for 4 weeks)
Trial: 239966
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose practolol (1.5 mg/kg)
Trial: 29885904
Drug: Haloperidol 5
RxNorm normalized name: haloperidol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 5 mg
Trial: 23504930
Drug: Short-term hormone
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term hormone therapy (futamide plus a luteinizing hormone-releasing hormone agonist for 4 months)
Trial: 14566568
Drug: Glucose ingested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose ingested 30 min before exercise (50 g)
Trial: 14566568
Drug: Glucose ingested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose ingested during exercise (110 g or 160 g in fractionated doses)
Trial: 14566568
Drug: Glucose ingested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose ingested both before and during exercise (50 g before and 110 g during)
Trial: 8770969
Drug: Sirolimus (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (1 to 3 mg/m2/day)
Trial: 8770969
Drug: Sirolimus (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (5 to 6 mg/m2/day)
Trial: 8770969
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg/m2/day)
Trial: 8770969
Drug: Sirolimus (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (any dose)
Trial: 1612040
Drug: Simethicone 65
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone 65 mg in 90 ml of water
Trial: 1612040
Drug: Simethicone 65
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone 65 mg in 30 ml of water
Trial: 1612040
Drug: Simethicone 195
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone 195 mg in 90 ml of water
Trial: 30879470
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation (CR) consisting of 10 therapy sessions over 3 months, followed by four maintenance sessions over 6 months.